We are live on ! Find out more

CPRX

Catalyst Pharmaceutical

CPRX

Delisted

CPRX was delisted on the 14th of July, 2026.

47 hedge funds and large institutions have $56.4M invested in Catalyst Pharmaceutical in 2014 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 14 increasing their positions, 3 reducing their positions, and 6 closing their positions.

New

Increased

Maintained

Reduced

Closed

367% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 3

335% more call options, than puts

Call options by funds: $87K | Put options by funds: $20K

150% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 6

138% more capital invested

Capital invested by funds: $23.7M → $56.4M (+$32.8M)

24% more funds holding

Funds holding: 38 → 47 (+9)

Holders

Holders Change

Holders Change %

+23.68%

% of All Funds

1.35%

Holding in Top 10

–

Holding in Top 10 Change

–

Holding in Top 10 Change %

–

% of All Funds

–

New

Increased

Reduced

Closed

Calls

$87K

Puts

$20K

Net Calls

+$67K

Net Calls Change

+$63K

Top Buyers

1	Franklin Resources San Mateo, California	+$5.53M
2	BC Broadfin Capital New York	+$5.13M
3	BBA Baker Bros. Advisors New York	+$3.53M
4	PA Perceptive Advisors New York	+$3.2M
5	VAM Visium Asset Management New York	+$3.2M

Top Sellers

1	Federated Hermes Pittsburgh, Pennsylvania	-$175K
2	U UBS Zurich, Switzerland	-$69.5K
3	CAN Cetera Advisor Networks El Segundo, California	-$54K
4	QIM Quantitative Investment Management Charlottesville, Virginia	-$25K
5	Morgan Stanley New York	-$7K

#	Name	Holding	Trade Value	Shares Change	Change in Stake
1	1 Federated Hermes Pittsburgh, Pennsylvania	$8.06M	-$175K	-82,000	-3%
2	2 Franklin Resources San Mateo, California	$6.55M	+$5.53M	+2,589,500	New
3	BC 3 Broadfin Capital New York	$6.07M	+$5.13M	+2,400,000	New
4	BBA 4 Baker Bros. Advisors New York	$5.62M	+$3.53M	+1,653,200	+290%
5	O 5 OrbiMed New York	$4.79M	–	–	–
6	6 Vanguard Group Malvern, Pennsylvania	$4.53M	+$328K	+153,782	+9%
7	PA 7 Perceptive Advisors New York	$3.79M	+$3.2M	+1,500,000	New
8	VAM 8 Visium Asset Management New York	$3.79M	+$3.2M	+1,500,000	New
9	OM 9 Opaleye Management Boston, Massachusetts	$3.49M	–	–	–
10	CCA 10 Catalyst Capital Advisors Huntington, New York	$2.1M	+$1.77M	+830,000	New
11	SC 11 Sophrosyne Capital New York	$1.52M	+$678K	+317,500	+112%
12	GTC 12 Ghost Tree Capital New York	$1.11M	+$507K	+237,296	+119%
13	13 Geode Capital Management Boston, Massachusetts	$751K	+$264K	+123,472	+71%
14	14 AQR Capital Management Greenwich, Connecticut	$608K	+$83.3K	+39,000	+19%
15	WMSA 15 Weiss Multi-Strategy Advisers New York	$531K	+$235K	+110,000	+110%
16	BFA 16 BlackRock Fund Advisors San Francisco, California	$402K	+$339K	+158,856	New
17	TCM 17 Tanaka Capital Management New York	$338K	–	–	–
18	18 Bank of New York Mellon New York	$313K	+$1.41K	+658	+0.5%
19	19 Susquehanna International Group Bala Cynwyd, Pennsylvania	$273K	+$231K	+107,933	New
20	20 Northern Trust Chicago, Illinois	$232K	+$31.7K	+14,856	+19%
21	21 Bank of America Charlotte, North Carolina	$191K	+$123K	+57,759	+328%
22	22 Invesco Atlanta, Georgia	$171K	+$144K	+67,393	New
23	PSC 23 Piper Sandler & Co Minneapolis, Minnesota	$127K	+$107K	+50,000	New
24	24 Deutsche Bank Frankfurt Am Main Ge, Germany	$126K	–	–	–
25	25 State Street Boston, Massachusetts	$120K	–	–	–

CPRX Hedge Fund Activity: Q2 2014 in Review

47 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q2 2014, worth a combined $56.4M — up 138% from $23.7M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new CPRX positions and 6 closed out — a net gain of 9 holders — while 14 added to existing stakes and 3 trimmed.

The largest buyer was Franklin Resources, opening a new position worth an estimated $5.53M. The largest seller was Federated Hermes, cutting an estimated $175K.

47 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q2 2014, up from 38 in Q1 2014.
Funds reported $56.4M of Catalyst Pharmaceutical stock for Q2 2014, up 138% quarter-over-quarter.
15 funds opened new Catalyst Pharmaceutical positions in Q2 2014 and 6 closed out, a net change of +9 holders.
The largest Catalyst Pharmaceutical buyer in Q2 2014 was Franklin Resources, an estimated $5.53M added.
The largest Catalyst Pharmaceutical seller in Q2 2014 was Federated Hermes, an estimated $175K sold.

Based on aggregated 13F filings for Q2 2014.

Catalyst Pharmaceutical CPRX